dvm360 product report: 15-month Lyme vaccine, practice app features and more
15-month duration of immunity claim for Lyme vaccine
The USDA has granted approval for a 15-month duration of immunity (DOI) claim for Vanguard crLyme, the longest DOI claim of any canine Lyme disease vaccine on the market, according to Zoetis. Vanguard crLyme vaccine is a multivalent recombinant Lyme vaccine to aid in the prevention of clinical disease and subclinical arthritis associated with Borrelia burgdorferi, the causative agent of Lyme disease in dogs. It contains outer surface protein A (OspA) protein and a single OspC protein composed of antigenic material from seven common types of OspC found in Lyme-infected dogs in the U.S.
Practice app notification features
Vet2Pet has released two new features for its veterinary app platform. The first, breed-specific notifications, lets veterinarians use their practice-branded mobile app to send notifications to owners of more than 100 canine and 10 feline breeds on such topics as medical conditions, breed-specific risks and recommended diets. Another new feature, custom list notifications, enables practices to send push notifications to specific groups of clients. For example, a practice could create a list of patients that haven’t had a heartworm test or a list of geriatric cats that haven’t had wellness bloodwork, and send specific notifications to these groups to increase compliance.
Vaccine resource center
Henry Schein Animal Health has launched its Companion Animal Vaccine Resource Center, a web-based hub that provides veterinarians with the latest data on infectious diseases in cats and dogs and critical information about the role regular vaccinations of pets play in protecting animal and human health. The resource center features updates on the geographic expansion of canine influenza, Lyme disease and leptospirosis; vaccination guidelines from AAHA and the American Association of Feline Practitioners; information from manufacturers such as Merck, Elanco, Merial and Zoetis on product offerings, rebate programs and warranties; an interactive quiz to help veterinarians determine how their vaccination practices stack up against their peers; and a regularly updated calendar of upcoming vaccine-related events.
Veterinary oncology market report
A new study from Brakke Consulting examines the No. 1 killer of dogs and cats: cancer. In the past decade, the U.S. has gone from zero cancer therapies approved for veterinary use to more than a half-dozen, with dozens more in development, Brakke experts say. The report, “Cancer in Dogs and Cats,” provides information on the incidence of cancer in pets, examines how cancer is diagnosed and treated in veterinary medicine, and offers estimated costs for treatment. It reviews FDA-approved cancer treatments now on the market along with developing veterinary cancer products, including therapies, diagnostics and supportive care. The report estimates the current sales of veterinary-approved cancer therapies and provides estimates of the total number of pets treated with chemotherapy or immunotherapy.